Travere Therapeutics

top of page

Sep 6

Travere's FILSPARI earned a conversion of its accelerated approval for IgA nephropathy into a full approval, a decision that came with an expanded label

CEO Eric Dube describes the drug's mechanism, the new population, and what else Travere is working on that will have near-term catalysts.

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

Visit Klein Hersh